Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$129.34 USD

129.34
264,662

+1.59 (1.25%)

Updated Aug 8, 2025 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ChemoCentryx Up on Encouraging Rare Disease Candidate Data

by Zacks Equity Research

ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Kinjel Shah headshot

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

by Kinjel Shah

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

Zacks Equity Research

Roche's NDA for SMA Drug Risdiplam Gets Priority Review

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.

Zacks Equity Research

Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy

by Zacks Equity Research

Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.

Zacks Equity Research

AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Calquence to treat CLL patients, based on positive data from two phase III studies.

Sanghamitra Saha headshot

Healthcare ETF (RYH) Hits New 52-Week High

by Sanghamitra Saha

This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

Zacks Equity Research

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

by Zacks Equity Research

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

Sweta Killa headshot

Top & Flop ETFs Halfway Through Q4

by Sweta Killa

The fourth quarter brings strong gains for Wall Street buoyed by easing U.S.-China trade worries, stronger-than-expected corporate earnings and Fed's third rate cut.

Sanghamitra Saha headshot

Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

by Sanghamitra Saha

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Zacks Equity Research

Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Zacks Equity Research

Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

by Zacks Equity Research

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

Zacks Equity Research

4 Biotech Stocks That Could Keep Beating Wall Street

by Zacks Equity Research

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

Zacks Equity Research

AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

by Sanghamitra Saha

Pharma sector wins in October, making these ETFs and stocks winners.

Sweta Killa headshot

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Sweta Killa

Sector ETF report for PBE

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q3 Earnings Results

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

Sanghamitra Saha headshot

Value Biotech ETFs & Stocks to Buy Now

by Sanghamitra Saha

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

Sweta Killa headshot

Healthcare ETF (IHF) Tops in October: 5 Best Stocks

by Sweta Killa

Inside the best performing stocks of the top ETF of October.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

by Sweta Killa

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Zacks Equity Research

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

by Zacks Equity Research

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

Zacks Equity Research

Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3

by Zacks Equity Research

Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.

Sweta Killa headshot

Biotech ETFs Surge on a Flurry of Positive News

by Sweta Killa

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.